ClinicalTrials.gg
RecruitingNCT02333110Updated May 12, 2026

GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors

An interventional study of spatially fractionated radiation therapy in Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.

02

Conditions studied

  • Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation
03

In context

Lead sponsor

Sir Mortimer B. Davis - Jewish General Hospital is the lead sponsor of 62 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with or cytologically confirmed . All malignant histologies/cytologies are eligible.
  • Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation
  • Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
  • of 0-2
  • Aged 18 years or older
  • Ability to sign and understand an form

Exclusion criteria

Exclusion Criteria:

  • Potentially curable patient
  • Previous palliative radiation with hypofractionation
  • Tumor located near the spinal cord or in the brain
  • Pregnant or nursing woman
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    GRID radiation therapy

    A single dose of 15-20Gys of spatially fractionated radiation therapy

    Radiation: spatially fractionated radiation therapy

Interventions

  • Radiationspatially fractionated radiation therapy

    A single dose of 15-20Gys of spatially fractionated radiation therapy

    Also known as: GRID radiation therapy

06

What researchers measure

Primary outcomes

  1. Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire

    Time frame: 3 months post treatment

Secondary outcomes

  1. Acute toxicity of treatment, as measured using the CTCAE grading system (v4.0)

    Time frame: 1 week

  2. Long-term toxicity of treatment, as measured using the CTCAE grading system (v4.0)

    Time frame: 3, 6, 9, 12 months

  3. Cost-effectiveness, as measured by evaluating the cost of the procedure per patient and the efficacy of treatment with regards to symptom relief and tumor response

    Time frame: 3 months

  4. Tumor response, measured on CT-scan

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Sir Mortimer Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Dec 2026 and a completion of Dec 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2014
First posted
Jan 7, 2015
Start
Jan 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02333110
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Responsible party
Dr. Te Vuong (Director, Radiation-oncology department, Sir Mortimer B. Davis - Jewish General Hospital) — Principal investigator
First posted
Jan 7, 2015
Start date
Jan 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 12, 2026

Study contacts

Luciana Poggi, PhD
Contact
luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca
514-340-8222 ext. 28443
Te Vuong, MD
principal investigator · Sir Mortimer Jewish General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion